Transfersomes as a Surfactant-based Ultradeformable Liposome

Akash Sharma[1], *Tarun* Yadav[1], *Oshin* Tickoo[1],*Kalvatala* Sudhakar [1,*], *Narendra* Pandey[1], *Pawan* gupta[2], *R* Narayana charyulu[3], *Azimullah* Wafa[4],*Prinsy* Rana[5]and*Monika*[6]

[1] School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India
[2]Department of Pharmaceutical Chemistry, Shri Vile Parle Kelavani Mandal's Institute of Pharmacy, Dhule, Maharashtra, India
[3]Department of Pharmaceutics, NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Mangaluru-575018, India
[4]Faculty of pharmacy, Kabul University, Kart-e-Char, Kabul, Afghanistan
[5]MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana, India
[6]Noida Institute of Engineering and Technology (Pharmacy Institute, Greater Noida, U.P., India

*Corresponding author: sudhakar.20477@lpu.co.in

Abstract. In the modern era, there are numerous ways for drug delivery. The change in time has led to the progress of drug delivery systems gaining significant development. Even though most of the drugs are administered orally i.e., in conventional dosage form it has its limitations too like poor patient compliance, metabolism in the liver's first passage, poor absorption, and fluctuations in plasma level.Because our skin is indeed the largest organ, transdermal medication administration has received increased attention in recent years. Many lipids nanovesicles like Liposomes, Niosome, Ethosome, and Transfersomes have been developed as a carrier for transdermal drug delivery. But out of them, Transfersomes are the ones which are of great interest as they show better permeation among all as most of the other carriers cannot pass through the stratum corneum. The method of transdermal medication administration has been used to provide controlled and targeted action and can act as topical and dermal preparation. This review provides basic information about Transfersomes, their mechanism of action, applications, and comparison with other lipid nanocarriers.

Keywords: Transfersome, Skin, Ultradeformable liposome, Transdermal, Surfactant

1 Introduction

Themost frequent route used fortaking drugsis the oral routewhich has been in use for the past many years and is commonly used as a conventional dosage form. Butthe oral route also has a few limitations such as poor patient compliance, pre-systemic metabolism, poor absorption, and fluctuations in plasma level.[1]So, to overcome this problem various drug delivery routes have been investigated for several drugs in the recent past, and the transdermal route of drug administration is onesuch approach. An essential component of systemic or localized effects is the transdermal system.[2],[3]

TDDSshowsseveral advantages on top of oral drug delivery, as they tend to achieve steady-state drug levels, bypass the pre-systemic metabolism inthe liver, increase patient compliance, and lesser gastrointestinal side effects[4]whereas transdermal skin patches may be readily applied to young ones and the elderly peoplesafely and easily. Additionally, the use of transdermal skin patches has improved adherence in older polypharmacy patients, who usually suffer from poor compliance due to the high daily pill load and swallowing problems.[5]Many dermatological disorders, likeskin cancer, contact dermatitis, and, psoriasis is now treated using TDDS. TDDS is also appropriate over a long period of administration, particularly for the delivery of analgesics and insulin. [6]The transdermal systems are also affordable and self-administrable. However, the number of drugs that may be adjusted for transdermal delivery limits this form of administration.[7]Passing the Stratum corneum for therapeutic agents is difficult as it behaveslike a barrier to skin permeation.So, a variety of methods, including, ultrasound, iontophoresis, micro-needling,

electroporation, and crucial usage of nanoencapsulation such as liposomes, have been developed to increase drug diffusion over the stratum corneum barrier. [8]

Dermal penetration may be improved by using polymeric carriers.[9]Vesicles are used in transdermal drug administration for a variety of reasons, including the fact that their makeup makes them penetration enhancers and drug carriers for delivering entrapped drug molecules through the skin. [10]There are numerous drug delivery methods currently available for the efficient administration of drugs through the skin, including solid lipid nanoparticles, nanostructured nanocarriers, and lipid nanovesicles (LNVs) with special features.[11]Liposomal vesicles, which are known as Solid Lipid nanoparticles, have a rigid surface; in contrast, liquid micelles are flexible in the system. Ethosomes, transfersomes, and transethosomes are a few of the vesicular transporters that make up the most recent generation of ultra-flexible carriers.[12]The transdermal delivery system is particularly interested in liposomes and similar formulations because they can deliver both hydrophilic and lipophilic drugs. [13]However conventional liposome penetration is confined to the higher skin layers i.e., Stratum corneum, therefore they produce an effect on the upper layers and are not a viable option for the transdermal administration of drugs.[14]Enhanced drug permeation and superior contact on the surface of the skin were observed as compared to traditional liposomes, as these elastic vesicles contain penetration enhancers. [3]Research on transdermal drug delivery has focused a lot on ultradeformable liposomes (ULs), a subset of lipid vesicle carriers. [15]

2 The Skin

Drugs may now be administered through the skin in addition to the more traditional oral or injectable routes. This is a result of the skin's huge, accessible surface area (1.5 m^2) and many additional benefits it provides as a safe route of drug administration.[16]Skin is typically less than 2 mm thick and accounts for up to 16% of body weight.[17]It also serves important metabolic, immunological, and sensorial functions Additionally, it performs crucial sensory, immunological, and metabolic tasks. [18]The epidermis, dermis, and subcutaneous layer are the three layers that make up the skin.The subcutaneous layer, which includes subcutaneous fat (hypodermis), is the first layer to appear from the inside out, after whichthe dermis appears, containing connective tissue, and, finally, the epidermis which is a cell layer without vascularization. [19]The epidermis, which is the skin's outermost layer, is made up of keratinocytes, which produce keratin and are involved in the desquamation process. These layers are avascular. [20]The epidermis of skin contains four different layers Stratum corneum is said to be the outermost layer while below it contains stratum granulosum, stratum spinosum, and the cavernous layer stratum basal. On the top of the palm and soles, an additional sublayer of skin is there that is Stratum lucidum. [21]The stratum corneum has (10–20 μm) thickness while the epidermis possesses a 0.1–0.2 mm thickness, and the viable epidermis has (50–150 μm). The highly organized, lipid-rich stratum corneum inhibits the entry and exit of chemicals, water, and oxygen.[22]



Fig. 1 Diagram of different skin layer structures

The body's initial and primary physical skin barrier is made up of the stratum corneum (10–20 m), the epidermis' outermost sublayer. It is made up of corneocyte-specific cells, which serve as the primary barrier against molecules passage larger than 500 Daltons through the skin. [23]

The SC works as a two-compartment system with a lamellar membrane extracellular matrix that is arranged in a "brick and mortar" pattern. Its essential roles include safeguarding against environmental dangers, producing vitamin D, and keeping the body's dynamic equilibrium. Passive diffusion, which may take place across the stratum corneum in three distinct ways (transcellular, intracellular, and appendageal), is the main mechanism by which substances are transported through it. The rate-limiting step for all chemicals entering the skin is diffusion through the stratum corneum. Below the stratum corneum, there is a viable epidermis (50–100 m), which may also block drug penetration. An important layer of the skin called the dermis (3-5 mm thick) has a capillary network that connects to the body's circulatory system. It gives the skin its thickness and aids in keeping the skin supple. [24]

3 Lipid nanovesicles for transdermal delivery

Vesicular systems for drug administration are a highly organized collection of lipids that contain water and one or more concentric bilayers of molecules. Vesicular systems, which include liposomes, niosomes, ethosomes, and, transfersomes are classified as particle-carrying systems. [11]

Liposomes

Alec Bangham first characterized the phospholipid bilayer systems—then called "bangosomes" but now called "liposomes"—that were the main subject of the disclosure. [12]Liposomes are lipid vesicles that have an aqueous core and a lipid bilayer to protect hydrophobic drugs from the environment.[11]In general, phospholipids with or without cholesterol make up their principal constituents. Two hydrophobic hydrocarbon chains and several polar head groups make up phospholipid molecules.[25]When conjugated with the ligand, they exhibit extremely excellent biocompatibility, a sustained-releasing profile, and drug-targeting qualities. A bonus benefit of using liposomes for drug delivery is that increasing the therapeutic ratio of the drugs used lessens the harmful effects of many different drugs. [26]Despite the increased therapeutic efficacy of liposomes, traditional liposomes are limited to the top layer of skin and are unable to penetrate deeper.[27]

Niosomes

Niosomes are microscopic, lamellar structures that resemble liposomes in shape and size and vary from 10 to 1000 nm. However, the non-ionic surfactants present in their bilayer, which give them their flexibility, make them more flexible.[28] These amphiphiles, sometimes referred to as surfactants, are non-ionic and have a structure that includes and have a structure that includes both a hydrophilic head and a hydrophobic tail.[21] Niosomes are more sophisticated liposomes in which non-ionic surfactants like Brij, Span, and Tween are used to replace the phospholipid. Niosomes can effectively get over liposome drawbacks including limited drug loading and chemical instability.[11] Niosomes may be administered orally, intramuscularly, intravenously, or transdermally.[29]Because they may extend the period that the drugstays in the epidermis and stratum corneum while reducing the quantity of drug that is absorbed into the body, these vesicles are beneficial in the topical distribution of pharmaceuticals.[29]Excipients such as cholesterol or its derivatives are often added to improve the fluidity and permeability of the bilayer while also boosting its stability. This helps safeguard the drugs against degradation or deactivation.[30]

Ethosomes

Ethosomes, the second generation of flexible phospholipids, were developed in the 1990s. Ethosomes are phospholipid- and ethanol-based nanovesicle carriers. Due to an irregular particle size distribution, they are only found in the epidermis and range from 30 nm to microns. [31]The volume and depth of drug administration to the skin may be improved using ethosomes more so than with conventional liposomes.[32] Patient compliance is high since ethosomal drugs are given in the semisolid form (gel or cream).[33] It is simple for drugs that are hydrophilic, lipophilic, or amphiphilic to get into ethosomes, where they may pass through the deeper epidermal layers and into circulation.[27] Because of its polar character, ethanol is a solvent that may interact directly with the stratum corneum's polar phospholipid head to lower the stratum corneum's melting point and increase drug absorption.[34]The ethanol in the ethosome crosses intracellular lipids, increasing the number of lipids that may dissolve in the cell membrane while

decreasing the amount of lipid density in the membrane cell layer. The lipophilic stratum corneum may also allow the ethosome's active component to get through.[35]Drug penetration through the skin is greater with ethosomes than with liposomes because ethanol can fluidize the membrane lipids of SC.[36]

4 Transfersomes

Transfersomes were first defined by a person named Gregor Cevc in 1991 as "highlydeformable self-adapting and flexiblevesicles that are bilayer in naturemadeof surfactant and phospholipids."[2]Transfersomesmeans carrying across a body It is made up of 2 words transferee and soma.[37]These first generations of elastic vesicles have been shown to deliver drugs through undamaged skin under non-occlusion situations.[38] Transfersomes, which are made of phospholipids plus a surfactant to add flexibility to the liposome structure, are also known as deformable or elastic liposomes.



Fig. 2 Diagrammatic representation of Transfersomes

These vesicles, which are more elastic than liposomes, squeeze through the lipid intercellular channels of the stratum corneum, the top layer of skin, to get past the barrier preventing access to the skin.[39]They are excellent options for regulated and targeted drug administration since they are metastable in nature and function as an artificial vesicle-like carrier designed to resemble a cell vesicle or a cell engaging in exocytosis. [40] Transfersomes are vesicular carriers specially designed in such a way that they have a minimum of one compartment which is aqueous in nature and engulfed within a lipid bilayer, along with the presence of an edge activator. Ultra-deformable vesicles have an aqueous core that is covered by a lipid bilayer, which allows them to self-regulate and self-optimize. As a result, transfersomes show elastic properties and can easily deform allowing them to constrict in the form of intact vesicles without undergoing any significant loss through constrictions or narrow pores of the skin which are much smaller as compared to vesicle size.[1]

A drug must havea molecular weight of less than 500 Da (Dalton) and proper lipophilicity for it to be efficiently administered through the skin passively.[29]The vesicle membrane's surfactants have a high degree of distortion, allowing them to pass through skin pores that are much smaller than they are. [24]The concentric bilayer deformability rises when the vesicle bilayeris destabilized, which is straight away related to the edge activator or surfactant containing a single chain having a high radius of curvature.[41]Due to their smaller size which is not more than 300nm and high elasticity which is 5-8 folds more as compared to liposomes andpass intracellularly through skin layers as they can easily deform.

Phosphatidylcholine is the lipid found in significant numbers within the cell membrane and is largelyutilized in the transfersomes manufacturing, hence leading to their higher tolerance of skin and lowering hypersensitivity, irritation, and/or side effects. These compounds generally include surfactants like sodium cholate, polysorbates, and

sodium deoxycholate. [19] The reason behind the vesicle's elasticity is the edge activator, as it weakens the vesicle's lipoidal bilayer and improves its deformability along with flexibility. Edge activators are high-curvature-radius single-chain surfactants. [25]Due to the skin's very flexible membranes, transfersomes can pass through it through diffusion without rupturing the vesicle. [42] Transfersomes are non-toxic, biocompatible, and capable of prolonged drug administration. [43]

Table. 1 Components Involved in Transfersomes Preparation[44]

S.No.	Component	Examples	Application
1.	Phospholipid	Dipalmitoyl phosphatidyl choline Soya phosphatidylcholine,	Helps in vesicle formation
2.	Alcohol	Methanol, Ethanol	Act as solvent
3.	Dyes	Rhodamine DPHE, rhodamine 123	For CSLM Study
4.	Buffering agents	Saline phosphate	For flexibility purpose
5.	Surfactant	Tween 80, Span 80, Sodium cholate	Helps to give flexibility

Merits

Greater ability to adapt for pore sizethanks to high efficiency.[45]Transfersomes carriers compriseboth hydrophobic as well as hydrophilic components, enablingthem to deliver medicinal agents with a broad solubility spectrum.They're made of EAs and natural phospholipids, as a result, show biocompatible and biodegradable properties. [1]They can easily bend and pass through constrictions 5-10 times smaller as compared to their diameter without undergoing any loss.Over 90% of thetargets can be entrapped by lipophilic drugs. They may use the transdermal method to administer drugs with both low and high molecular weights. [29]Helpful for administering medication topically and internally.They are suitable for cutaneous delivery because of their elastic nature, which also lowers the possibility of total vesicle rupture. [46]

De- Merits

Chemical compositions may sometimes degrade by oxidation, making them unstable. Transfersomes reorganization is related to the natural phospholipid's purity.[45] Transfersomal preparations are expensive in nature.[29]

5 Mechanism of action

Since water evaporates as soon as a lipid solution is applied to the skin's surface, the development of an osmotic gradient is what allows transfersomes to penetrate the skin. Transfersomes have an enhanced capacity for adhesion and water retention and demonstrate significant bilayer deformability.[12]



Fig. 3 Mechanism of transfersomes penetration across the skin.

6 Preparation methods

Thin-Film Hydration

This particular method is also referred to as the rotating evaporation technique. In a solvent like chloroform, the phospholipid and edge activator are mixed in the correct amounts after being weighed out. The resultant solution is then added to the rotating flask, which rotates while maintaining a reduced pressure and a steady temperature.As the organic solvent evaporates, a thin layer develops on the flask's bottom. The lipid vesicles in the generated film are then thoroughly hydrated using an aqueous solution and drug. Necessary particle size are obtained via sonication or extrusionprocess.[21]

Vortexing-Sonication Method

In this technique, edge activators and phospholipidsare combined and vigorously agitated before they are suspended in a phosphate buffer. Then using a bath sonicator or vortex, the prepared suspension is sonicated. This is subsequently extruded through membranes of varying diameters to generate vesicles of the desired size.[47]

Ethanolinjection method

An excess of the aqueous solution is swiftly injected with a tiny needle into a lipid solution in the organic solvent. Using this method, a relatively high proportion of SUVs with around 25 to 30 nm diameter were created. The simplicity of the technique and the lack of any potentially damaging physical processing are its benefits. The primary drawback is that the residual solvent in the aqueous phase must be removed using gel filtering or dialysis.[19]

Solvent evaporation method

Ethyl acetate and the polymer are mixed in this process because it has a superior toxicological profile than chloroform and dichloromethane. After that, an aqueous phase is used to emulsify the resultant solution. A lipid solution in an organic solvent is swiftly injected with the aid of a small needle into an excess of the aqueous solution. Using a constant magnetic stirring the liquid is evaporated,and the created nanoparticles will be cleaned and collected by centrifuging as soon as the solvent has evaporated. Following this, freeze-drying will be used for long-term storage.[48]

Modified Handshaking Method

The first beakerincludes the appropriate amount of surfactant (edge activator), Lecithin (phospholipid), and the drug, while the second beakercontains the chloroform and ethanol in an equal1:1 ratio. Then the contents present inboth beakers are combined. A little needle is used to swiftly inject a lipid solution in an organic solvent into an excess of the aqueous solution. The thin lipid layer that formed as a consequence of evaporation is kept during the night to completely remove the organic solvent. After adding a buffer to the thin layer, it is further hydrated, and then moderate shaking is done for 15 minutes. Now, the suspension is hydrated for a few hours at 80°C.[49]

Reverse phase evaporation

In this procedure, aqueous media containing surfactants and lipids containing organic solvents are combined in a round-bottom flask., the drug is then added to an aqueous or lipid mediumbased on the drug's solubility. After the mixture has been sonicated, further solvent removal is carried out at low pressure.[48]

Centrifugation process

It is combined with the lipophilic drug, catalyst, and phospholipids. A rotatory evaporator is employed at lower pressure and temperature to remove the solvent. Keeping them in the dark prevents the removal of solvents. During the centrifugation procedure, the settled lipid film is moistened using a suitable buffer solution. Drug penetration of hydrophilic substances occurs during this period. These vesicles enlarge when the temperature is ambient. A sonication process is used to create multilamellar lipid vesicles. [50]

Suspension Homogenization Method

By mixingthe edge activator with therequired amount of ethanolic phospholipid solution transfersomes are prepared. Thesuspension formed is combined with buffer to yield a complete lipid concentration. Further sonicated, frozen, and thawed resulting formulation respectively 2-3 times.[1]

High-pressure homogenization

Continuous mixing of the medication and edge activator for phospholipids occurs in distilled water. Through the use of ultrasound, the mixture is stirred. After that, the resultant slurry is homogenized under high pressure. The transfersomes are lastly adequately maintained.[50]

7 Evaluation parameters

Morphology and Size of Vesicles

Numerous factors, including ionic strength, phospholipid content, mode of synthesis, temperature, hydration of lipids in aqueous medium pH, etc., affect the vesicle size and morphological characteristics. Vesicles are categorized based on their size and lamellarity. Small unilamellar vesicles are 200 nm in size or less; anything more than this is referred to as a large unilamellar vesicle. They may either be multivesicular vesicles or multilamellar vesicles depending on the lamellarity.[11]

Entrapment Efficiency (EE)

Any formulation must have the ability to entrap the drug in vesicles. Strongly hydrophilic drugs are deposited in the aqueous compartment, whereas pharmaceuticals having a higher lipophilicity are confined inside the lipid layer (i.e., aqueous core). The aqueous and lipid phases of drugs have intermediate log P values (i.e., both, in the aqueous and the bilayer core). If the vesicular membrane's integrity is harmed, a decline in EE can happen, which might lead to drug loss.Numerous factors, such as the vesicle's size, the kind of phospholipids used, the ratio of bilayer components, the pH, etc., affect the EE of the vesicles. It is examined using techniques to extract the free drugs from vesicles, including ultracentrifugation, gel chromatography, mini-column centrifugation, ultrafiltration, and dialysis. According to studies, entrapment efficiency research using ultracentrifugation is less accurate, sensitive, and selective than other methods. The distortion of vesicles during ultracentrifugation is blamed for their selectivity and sensitivity. The vesicles are ruptured after separation using N propanol or 0.1% Triton X-100. The equation's formula is used to calculate entrapment efficiency. [47]

$$\text{Entrapment Efficiency} = \frac{\text{Amount of drug entrapped}}{\text{The total amount of drugs added}} \times 100$$

The number of vesicles per cubic mm:

For the combination and other operational factors to be optimized, this is a crucial parameter. To study transfersome formulations (without sonication) using optical microscopy and a hemocytometer, dilute them five times using a 0.9% NaCl solution. Then, using the formula below, determine how many vesicles are present in each cubic millimeter.[44]

$$\text{Total no of transfersomes} = \frac{\text{Factor} \times 4000 \text{ per cubic mm}}{\text{The total number of square counteed}}$$

Surface Charge and Charge Density

- Using a zeta sizer, one may find the chargedensity and surface charge of Transfersomes.
- TEM and SEM can be used to visualize transfersomes.
- Dynamic light scattering and photon correlation spectroscopy can be employed to determine size distribution and particle size (PCS).
- Thedrug entrapment effectiveness of transfersomes may be assessed using the ultracentrifugation method.
- The size and structure of the vesicles over time may be used to assess vesicle stability, and HPLC or spectrophotometric techniques can be used to measure drug content.
- It is possible to assess drug release in vitro using a diffusion cell or a dialysis technique. [51]

Deformability index

Extrusion measurement may be used to determine the elasticity of deformable vesicles. The extruded vesicles are forced under steady pressure through a polycarbonate membrane filter with a predetermined pore size. The following equation is used to represent the elasticity of the vesicles in terms of the deformability index.

$$\text{Deformability index} = J(rv/rp)$$

Where rp is the pore size of the filter membrane, rv is the size of the vesicle after extrusion, and j is the weight of the dispersion extruded through a polycarbonate filter with a certain pore size.[52]

Occlusion Effect

The idea behind the blocking of transfersomes via the skin is beneficial for drug absorption. Vesicles permeate through the skin mostly because of hydro taxis (water movement). Occlusion stops water from the skin from evaporating[49]

Vesicles Type

To view transfersome vesicles, employ phase contrast microscopy and TEM. Vesicles' capacity is based on their shape and size. DLS determines the mean size, while TEM determines structural differences. [50]

In-vitro drug release

In vitro testing is done to measure the penetration rate. The formulation is optimized using in vitro data such as time to steady-state permeation and steady-state permeation flow before doing expensive in vivo testing. A suspension of transfersomes grown at 32℃ is extracted to measure drug release using a small column centrifuge. By multiplying the original drug entrapped by zero, the amount of drug released is calculated (100 percent entrapped and 0 percent released). [53]

8 Applications of transfersomes as the transdermal delivery system

Delivery of Antioxidants

In 2019, Wu et al. used the high-pressure homogenization technique to produce transfersomes that contained resveratrol. The developed transfersomes were shown to increase the safety, solubility, stability, and bioavailability of resveratrol. [1]

Carrier for Protein and Peptides

Transfersomes are the carriers of proteins and peptides such asbovine serum albumin, vaccines, insulin, etc. Normally, unbroken mammalian skin does not allow for the passage of proteins or other substances. Despite this, if these macromolecules are linked to the particularly tailored and ultra-deformable agent carriers, it evokes antibodies against the subcutaneously administered proteins, such as fluorescein-isothiocyanate-labelled bovine serum albumin.

The problem of non-invasive delivery of such molecules may be solved by combining the integral membrane proteins with an ultra-deformable membrane. For instance, including gap junction protein (GJP) intransfersomes causes the strongest immunological reaction to this particular class of macromolecule. The transfersomal distribution of peptides is a particularly efficient technique for the non-invasive therapeutic use of such high molecular weight drugs on the skin. When properly calibrated, transfersome-associated insulin (transfersulin TM) is administered across the skin with an effectiveness of >50%, and typically >80%, according to the synthesis and assessment of insulin-loaded transfersome.[54]

Vaccine delivery

According to some reports, transfersomes not only help an antigen pass through undisturbed skin, but they also transport the integrated antigen to the lymphatic circulation, where it is then carried to the lymph nodes. Tetanus toxoid vaccine delivery via transfersomes has been investigated, and it is effective at transporting the toxoid over the skin. Additionally, the development of antigens for transcutaneous immunization using transfersomes has been studied. Transfersomes made of human serum albumin and GJP were able to effectively elicit a humoral immune response in mouse models, leading to antibody levels that were on par with those reached by subcutaneous injection. Additionally, transfersomes' capacity to transport genetic material and perform transfection has been shown.[55]

Delivery of interferon (INF)

Increased stability of labile drugs and controlled release of drugs can be accomplished by using transfersomes as drug delivery devices. Transfersomes made of human serum albumin and GJP were able to effectively elicit a humoral immune response in mouse models, leading to antibody levels that were on par with those reached by subcutaneous injection. Additionally, transfersomes' capacity to transport genetic material and perform transfection has been shown.[56]

Transfersomes: An Effective Transporter of Anticancer Agents

The options for treating skin cancer have increased thanks to TFS. Researchers have revealed that sulforaphane-loaded vesicles of transfersome have antiproliferative effects against skin cancer. The capacity of sulforaphane to prevent the spread of human SKMEL 28 cancer cells was examined. Another study found that 5-fluorouracil transfersomal gel outperforms the currently available dosage form in terms of penetration and bioavailability experiment revealed that transfersomes had good cancer cell selectivity.[57]

Delivery of Biological Products (Insulin)

The development of transfersomes for other anti-diabetic drugs, such as metformin and repaglinide, which have greater skin permeability, has also been the subject of several investigations. According to studies by Malakar Jadupati et al., insulin is administered as a transfersomal gel. The lipid-to-surfactant ratio, skin texture, the lipophilicity of the drug, etc. are a few examples of the variables that impacted the flow of insulin penetration. [49]

Delivery of NSAIDs

Numerous GI adverse effects are linked to NSAID use. Transdermal distribution employing ultra-deformable vesicles can get around these problems. Diclofenac and Ketoprofen have both been researched. In 2007, the Swiss regulatory agency (Swiss Medic) approved the sale of ketoprofen in a formulation with transfersomes.[59] The medication will likely be sold under the brand name Diractin. According to IDEA AG, new drugs using the transfersomes technology are now undergoing clinical trials.[60]

Delivery of corticosteroids

Transfersomes may be used to administer corticosteroids. The site-specificity and overall safety of epicutaneous drug delivery are improved by transfersomes. [53]

Transdermal immunization

Transdermal immunization, which uses transfersomes loaded with soluble proteins such as integral membrane protein, human serum albumin, and gap junction protein, is a crucial use for transfersomes.[61-63] These techniques have relatively high titers and, presumably, immunoglobulin A levels, and they may be used without an injection. These are at least two advantages. [53]

Delivery of anaesthetics

When applied correctly, topical anesthesia is produced within 10 minutes after transfersome application that contains anesthetics. As we said in the case of pain in sensitivity, the impact is almost as great (80%) as with a comparable subcutaneous bolus injection, but the effects of transfersomal anesthetics formulation are more long-lasting.[56]

TABLE 2. Example of prepared transfersomes formulation[49]

S.no.	Drug	Drug category	Study-related	Results
1	Betamethasone	Steroid	Entrapment efficiency	Increased entrapment efficiency
2	5-fluorouracil	Anti-Cancer	Skin permeation and deposition	Improved flux rate b) Sustained drug release
3	18β-glycyrrhizic acid	Dermatitis	Permeation study. b) Anti-inflammation study.	Shows anti-inflammatory activity. b) 5 times greater than conventional vesicles.
4	5-Aminolevulinic acid	Photodynamic therapy	Skin retention study	Improve drug retention.
5	Benzocaine	Local anesthetic	Entrapment efficiency	Increased drug loading

9 Conclusion

Transfersomes are very deformable vesicles that may be used to transport high molecular weight drugs that cannot be administered transdermally due to the skin's barrier properties. Deformable particles called transfersomes may transport drugs over biological permeation barriers like the skin. These adaptable vesicles take on many shapes when they enter the skin via pores. They are particularly efficient in delivering proteins and peptides. These Transfersomes may pass through much smaller skin pores than typical to adjust to environmental stress. This enhances the transdermal flow of pharmaceuticals. Because of the combination of hydrophobic and hydrophilic molecules in their structure, transfersomes can dissolve in a variety of solutions. In comparison to other vesicles, transfersomes have a variety of advantages, including systemic drug release, skin penetration, stability, and deformability. Compared to transfersomes, other vesicular systems are less effective and secure. Transfersomes are more reliable and efficient than other vesicular carriers. In the review mentioned above, we took a close look at several facets of this transdermal delivery system, including current publications, production methods, characterization, and other elements.

10 References

1. S.A.T. Opatha, V. Titapiwatanakun, and R. Chutoprapat, “Transfersomes: A promising nanoencapsulation technique for transdermal drug delivery,” Pharmaceutics 12(9), 1–23 (2020).

2. N. Dudhipala, R. Phasha Mohammed, A. Adel Ali Youssef, and N. Banala, “Effect of lipid and edge activator concentration on development of aceclofenac-loaded transfersomes gel for transdermal application: in vitro and ex vivo skin permeation,” Drug Dev Ind Pharm, 1334–1344 (2020).

3. S. Babaie, A.R. del Bakhshayesh, J.W. Ha, H. Hamishehkar, and K.H. Kim, "Invasome: A novel nanocarrier for transdermal drug delivery," Nanomaterials 10(2), (2020).

4. B. Chaulagain, A. Jain, A. Tiwari, A. Verma, and S.K. Jain, "Passive delivery of protein drugs through transdermal route," Artif Cells Nanomed Biotechnol 46(sup1), 472–487 (2018).

5. A.Z. Alkilani, J. Nasereddin, R. Hamed, S. Nimrawi, G. Hussein, H. Abo-Zour, and R.F. Donnelly, "Beneath the Skin: A Review of Current Trends and Future Prospects of Transdermal Drug Delivery Systems," Pharmaceutics 14(6), (2022).

6. Z. Yu, X. Meng, S. Zhang, Y. Chen, Z. Zhang, and Y. Zhang, "Recent progress in transdermal nanocarriers and their surface modifications," Molecules 26(11), (2021).

7. B.A. Witika, L.L. Mweetwa, K.O. Tshiamo, K. Edler, S.K. Matafwali, P. V. Ntemi, M.T.R. Chikukwa, and P.A. Makoni, "Vesicular drug delivery for the treatment of topical disorders: current and future perspectives," J Pharm Pharmacol 73(11), 1427–1441 (2021).

8. M. Yuan, J. Niu, Q. Xiao, H. Ya, Y. Zhang, Y. Fan, L. Li, and X. Li, "Hyaluronan-modified transfersomes based hydrogel for enhanced transdermal delivery of indomethacin," Drug Deliv 29(1), 1232–1242 (2022).

9. M. Pradhan, S. Srivastava, D. Singh, S. Saraf, S. Saraf, & Manju, and R. Singh, Perspectives of Lipid-Based Drug Carrier Systems for Transdermal Delivery (2018).

10. C. Zylberberg, and S. Matosevic, "Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape," Drug Deliv 23(9), 3319–3329 (2016).

11. A. Raj, S.C. C, A.N. V, A. Ivon, N.F.N. M, and N.N.P. P, "Lipid-Based Vesicles: a Non-invasive Tool for Transdermal Drug Delivery," J Pharm Innov, (2021).

12. K. Sudhakar, S. Fuloria, V. Subramaniyan, K. v. Sathasivam, A.K. Azad, S.S. Swain, M. Sekar, S. Karupiah, O. Porwal, A. Sahoo, D.U. Meenakshi, V.K. Sharma, S. Jain, R.N. Charyulu, and N.K. Fuloria, "Ultraflexible liposome nanocargo as a dermal and transdermal drug delivery system," Nanomaterials 11(10), (2021).

13. A.T. Jamadar, M.R. Peram, N. Chandrasekhar, A. Kanshide, V.M. Kumbar, and P. v. Diwan, "Formulation, Optimization, and Evaluation of Ultradeformable Nanovesicles for Effective Topical Delivery of Hydroquinone," J Pharm Innov, (2022).

14. M. Qindeel, M.H. Ullah, Fakhar-ud-Din, N. Ahmed, and A. ur Rehman, "Recent trends, challenges and future outlook of transdermal drug delivery systems for rheumatoid arthritis therapy," Journal of Controlled Release 327, 595–615 (2020).

15. T. Subongkot, B. Pamornpathomkul, T. Rojanarata, P. Opanasopit, and T. Ngawhirunpat, "Investigation of the mechanism of enhanced skin penetration by ultradeformable liposomes," Int J Nanomedicine 9(1), 3539–3550 (2014).

16. F. Lai, C. Caddeo, M.L. Manca, M. Manconi, C. Sinico, and A.M. Fadda, "What's new in the field of phospholipid vesicular nanocarriers for skin drug delivery," Int J Pharm 583, (2020).

17. A. Williams, E.L. Romero, and M.J. Morilla, Carrier Deformability in Drug Delivery Maria Jose Morilla Related Papers Vesicular Syst Ems for Delivering Convent Ional Small Organic Molecules and Larger Macromole… Carrier Deformability in Drug Delivery (2016).

18. C. Vitorino, J. Sousa, and A. Pais, "Overcoming the Skin Permeation Barrier: Challenges and Opportunities," Curr Pharm Des 21(20), 2698–2712 (2015).

19. E.B. Souto, A.S. Macedo, J. Dias-Ferreira, A. Cano, A. Zielińska, and C.M. Matos, "Elastic and ultradeformable liposomes for transdermal delivery of active pharmaceutical ingredients (Apis)," Int J Mol Sci 22(18), (2021).

20. M. Elmowafy, "Skin penetration/permeation success determinants of nanocarriers: Pursuit of a perfect formulation," Colloids Surf B Biointerfaces 203, (2021).

21. D. Patel, B. Patel, and H. Thakkar, "Lipid Based Nanocarriers: Promising Drug Delivery System for Topical Application," European Journal of Lipid Science and Technology 123(5), (2021).

22. H.A.E. Benson, J.E. Grice, Y. Mohammed, S. Namjoshi, and M.S. Roberts, "Topical and Transdermal Drug Delivery: From Simple Potions to Smart Technologies," Curr Drug Deliv 16(5), 444–460 (2019).

23. V. Krishnan, and S. Mitragotri, "Nanoparticles for topical drug delivery: Potential for skin cancer treatment," Adv Drug Deliv Rev 153, 87–108 (2020).

24. S.R. Stefanov, and V.Y. Andonova, "Lipid nanoparticulate drug delivery systems: Recent advances in the treatment of skin disorders," Pharmaceuticals 14(11), (2021).

25. X. Zhou, Y. Hao, L. Yuan, S. Pradhan, K. Shrestha, O. Pradhan, H. Liu, and W. Li, "Nano-formulations for transdermal drug delivery: A review," Chinese Chemical Letters 29(12), 1713–1724 (2018).

26. I.A. Chacko, V.M. Ghate, L. Dsouza, and S.A. Lewis, "Lipid vesicles: A versatile drug delivery platform for dermal and transdermal applications," Colloids Surf B Biointerfaces 195, (2020).

27. L.M. Thomas, and A.H. Khasraghi, "Nanotechnology-based topical drug delivery systems for management of dandruff and seborrheic dermatitis: An overview," Iraqi Journal of Pharmaceutical Sciences 29(1), 12–32 (2020).

28. S. Khogta, J. Patel, K. Barve, and V. Londhe, "Herbal nano-formulations for topical delivery," J Herb Med 20, (2020).

29. A. Madni, M. Sarfraz, M. Rehman, M. Ahmad, N. Akhtar, S. Ahmad, N. Tahir, S. Ijaz, R. Al-Kassas, and R. Löbenberg, Liposomal Drug Delivery: A Versatile Platform for Challenging Clinical Applications (2014).

30. N. Akhtar, Send Orders for Reprints to Reprints@benthamscience.Net Vesicles: A Recently Developed Novel Carrier for Enhanced Topical Drug Delivery (2014).

31. G. Gaynanova, L. Vasileva, R. Kashapov, D. Kuznetsova, R. Kushnazarova, A. Tyryshkina, E. Vasilieva, K. Petrov, L. Zakharova, and O. Sinyashin, "Self-assembling drug formulations with tunable permeability and biodegradability," Molecules 26(22), (2021).

32. S.L. Jyothi, K.L. Krishna, V.K. Ameena Shirin, R. Sankar, K. Pramod, and H. V. Gangadharappa, "Drug delivery systems for the treatment of psoriasis: Current status and prospects," J Drug Deliv Sci Technol 62, (2021).

33. M. Bragagni, N. Mennini, F. Maestrelli, M. Cirri, and P. Mura, "Comparative study of liposomes, transfersomes and ethosomes as carriers for improving topical delivery of celecoxib," Drug Deliv 19(7), 354–361 (2012).

34. S.M. Jadhav, P. Morey, M.M. Karpe, and V. Kadam, "NOVEL VESICULAR SYSTEM: AN OVERVIEW," J Appl Pharm Sci 2012(01), 193–202 (n.d.).

35. B. Ewert de Oliveira, O.H. Junqueira Amorim, L.L. Lima, R.A. Rezende, N.C. Mestnik, E. Bagatin, and G.R. Leonardi, "5-Fluorouracil, innovative drug delivery systems to enhance bioavailability for topical use," J Drug Deliv Sci Technol 61, (2021).

36. L. Azzahra, S.R. Mita, and S. Sriwidodo, "Formulation, Characterization, and Herbal Drug Delivery Applications of Ethosome, Transfersome, and Transethosome," Indonesian Journal of Pharmaceutics 2(3), (2020).

37. M. Nagpal, and M. Kaur, "Nanomaterials for skin antifungal therapy: An updated review," J Appl Pharm Sci 11(Supplement 1), 15–25 (2021).

38. R. Garg, S. Kaur, Ritika, S. Khatoon, Naina, and H. Verma, "A complete and updated review on various types of drug delivery systems," International Journal of Applied Pharmaceutics 12(4), 1–16 (2020).

39. M. Gupta, U. Agrawal, and S.P. Vyas, "Nanocarrier-based topical drug delivery for the treatment of skin diseases," Expert Opin Drug Deliv 9(7), 783–804 (2012).

40. R. Bangia, G. Sharma, S. Dogra, and O.P. Katare, "Nanotechnological interventions in dermatophytosis: from oral to topical, a fresh perspective," Expert Opin Drug Deliv 16(4), 377–396 (2019).

41. S. Chauhan, N. Gulati, and U. Nagaich, "Fabrication and evaluation of ultra deformable vesicles for atopic dermatitis as topical delivery," International Journal of Polymeric Materials and Polymeric Biomaterials 68(5), 266–277 (2019).

42. I. Khan, R. Needham, S. Yousaf, C. Houacine, Y. Islam, R. Bnyan, S.K. Sadozai, M.A. Elrayess, and A. Elhissi, "Impact of phospholipids, surfactants and cholesterol selection on the performance of transfersomes vesicles using medical nebulizers for pulmonary drug delivery," J Drug Deliv Sci Technol 66, (2021).

43. M. Pradhan, D. Singh, and M.R. Singh, "Novel colloidal carriers for psoriasis: Current issues, mechanistic insight and novel delivery approaches," Journal of Controlled Release 170(3), 380–395 (2013).

44. C. Yang, X. Dai, S. Yang, L. Ma, L. Chen, R. Gao, X. Wu, and X. Shi, "Coarse-grained molecular dynamics simulations of the effect of edge activators on the skin permeation behavior of transfersomes," Colloids Surf B Biointerfaces 183, (2019).

45. R. Pahwa, S. Pal, K. Saroha, P. Waliyan, and M. Kumar, "Transferosomes: Unique vesicular carriers for effective transdermal delivery," J Appl Pharm Sci 11(5), 1–8 (2021).

46. D.K. Mishra, R. Shandilya, and P.K. Mishra, "Lipid based nanocarriers: a translational perspective," Nanomedicine 14(7), 2023–2050 (2018).

47. P. Vikas, S. Ajay, G. Dilip, S. Rajesh, and R. Khalsa, Ultra-Resilient Nanovesicular Systems: As a Novel Tool in Successful Transdermal Drug Delivery (2012).

48. V. Garg, H. Singh, S. Bimbrawh, S.K. Singh, M. Gulati, Y. Vaidya, and P. Kaur, "Ethosomes and Transfersomes: Principles, Perspectives and Practices," Curr Drug Deliv 14(5), (2016).

49. R. Pandey, M. Bhairam, S.S. Shukla, and B. Gidwani, "Colloidal and vesicular delivery system for herbal bioactive constituents," DARU, Journal of Pharmaceutical Sciences 29(2), 415–438 (2021).

50. R.S. Kumar, and M. Pradhan, "Transferosomes: Vesicular Carrier for both Hydrophilic and Lipophilic Drugs," J Pharm Res Int, 106–120 (2022).

51. J. Rajkumar, R.K. Sree Lakshmi, S. Vineesha, and J. Rajkumar, "A New Approach to Transdermal Drug Delivery Using Transfersomes-Based Nanoencapsulation: A Research Update," Asian Journal of Pharmaceutical Research and Development 10(1), 64–70 (2022).

52. M. Bhavika Bhokare, Transfersomes: A Novel Drug Delivery System (2017).

53. G.P. Kumar, and P.R. Rao, Ultra Deformable Niosomes for Improved Transdermal Drug Delivery: The Future Scenario (n.d.).

54. L. Kirana Pallathadka, and H. Pallathadka, JOURNAL OF CRITICAL REVIEWS NOVEL CARRIER FOR TRANSDERMAL PATCHES USED IN TRANSFEROSOMES: A REVIEW (n.d.).

55. M.J.S. Pawar, A.B. Roge, and S.M. Vadvalkar, "Novel Approach in Transdermal Drug Delivery System: Transferosome," Research J. Pharm. and Tech 6(1), (2013).

56. A. Kumar, K. Pathak, and V. Bali, "Ultra-adaptable nanovesicular systems: A carrier for systemic delivery of therapeutic agents," Drug Discov Today 17(21–22), 1233–1241 (2012).

57. P. Chaurasiya, E. Ganju, N. Upmanyu, S.K. Ray, and P. Jain, "Transfersomes: a novel technique for transdermal drug delivery," Journal of Drug Delivery and Therapeutics 9(1), 279–285 (2019).

58. M.W. Akram, H. Jamshaid, F.U. Rehman, M. Zaeem, J. zeb Khan, and A. Zeb, "Transfersomes: a Revolutionary Nanosystem for Efficient Transdermal Drug Delivery," AAPS PharmSciTech 23(1), (2022).

59. Sharma, R., Jasrotia, K., Singh, N., Ghosh, P., Srivastava, S., Sharma, N.R., Singh, J., Kanwar, R. and Kumar, A., 2020. A comprehensive review on hydrothermal carbonization of biomass and its applications. *Chemistry Africa*, *3*, pp.1-19.

60. Khursheed, R., Singh, S.K., Wadhwa, S., Kapoor, B., Gulati, M., Kumar, R., Ramanunny, A.K., Awasthi, A. and Dua, K., 2019. Treatment strategies against diabetes: Success so far and challenges ahead. *European journal of pharmacology*, *862*, p.172625.

61. Jena, M.K., Nayak, N., Chen, K. and Nayak, N.R., 2019. Role of macrophages in pregnancy and related complications. *Archivumimmunologiae et therapiaeexperimentalis*, *67*, pp.295-309.

62. Singh, P., Nayyar, A., Kaur, A. and Ghosh, U., 2020. Blockchain and fog based architecture for internet of everything in smart cities. *Future Internet*, *12*(4), p.61.

63. Manzoor, S.I. and Singla, J., 2019, April. Fake news detection using machine learning approaches: A systematic review. In *2019 3rd international conference on trends in electronics and informatics (ICOEI)* (pp. 230-234). IEEE.